TY - JOUR
AU - Chen, Baihua
AB - PurposeTo assess the effectiveness and safety of continuous lavage with 1% voriconazole (CL) for moderate and severe fungal keratitis.MethodsThirty-one patients were randomized to receive topical eye drops either alone (T) or combined with continuous 1% voriconazole lavage (CL-T). The primary outcome was the cure rate at 3 months. The secondary outcomes were the 6-day efficacy, 3-day infiltration size and depth, hypopyon height, central corneal thickness (CCT), epithelial defect size, and subject feelings and clinical signs assessment scores.ResultsAt 3 months, the cure rate was comparable between the groups in patients with moderate fungal keratitis (66.7% vs. 62.5%, P = 0.60). However, among severe cases, 4 cases (44.4%) in the CL-T group healed successfully, while none in the T group; this difference was not significant (P = 0.08), although it was very close to 0.05. This may be related to the small sample size. After 6 days, the percentage of patients with “worsened” ulcers in the CL-T group was lower than that in the T group (0% vs. 31%, P = 0.043). The infiltration size, infiltration depth, and hypopyon height in the CL-T group were smaller than those in the T group after 3 days (all P < 0.05). There was no difference in CCT, epithelial defect size, subject feelings scores, or clinical signs scores between groups.ConclusionThese outcomes suggest that CL is an effective and safe adjuvant method for controlling the progression of moderate and severe fungal keratitis.Trial registration numberChiCTR2100050565.[graphic not available: see fulltext]
TI - Continuous voriconazole lavage in managing moderate and severe fungal keratitis: a randomized controlled trial
JF - Graefe s Archive for Clinical and Experimental Ophthalmology
DO - 10.1007/s00417-022-05969-z
DA - 2023-06-01
UR - https://www.deepdyve.com/lp/springer-journals/continuous-voriconazole-lavage-in-managing-moderate-and-severe-fungal-4dkjpZ42J0
SP - 1639
EP - 1649
VL - 261
IS - 6
DP - DeepDyve
ER -